Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more

An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·3h ago
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/54dadf0c77d14fcabab17534c0f1e597376bbbd5"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a Biogen Alzheimer&#8217;s drug, skyrocketing 340B drug sales, and more"></iframe>

STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more

More from Health

STAT+: In a major policy shift, Medicare proposes to ban vendors from providing remote monitoring services

Cancer disparities researchers say federal funding changes have disrupted their work

STAT+: Celcuity’s breast cancer drug approved, its first

Deaths from coronary artery disease have fallen, but more progress is within reach

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about a Biogen Alzheimer&#8217;s drug, skyrocketing 340B drug sales, and more

More from Health

STAT+: In a major policy shift, Medicare proposes to ban vendors from providing remote monitoring services

Cancer disparities researchers say federal funding changes have disrupted their work

STAT+: Celcuity&#8217;s breast cancer drug approved, its first

Deaths from coronary artery disease have fallen, but more progress is within reach

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more

STAT+: Celcuity’s breast cancer drug approved, its first